NO336459B1 - Markørproteiner og in vitro metoder for diagnostisering av leversykdom og metoder for måling av protein. - Google Patents
Markørproteiner og in vitro metoder for diagnostisering av leversykdom og metoder for måling av protein.Info
- Publication number
- NO336459B1 NO336459B1 NO20052992A NO20052992A NO336459B1 NO 336459 B1 NO336459 B1 NO 336459B1 NO 20052992 A NO20052992 A NO 20052992A NO 20052992 A NO20052992 A NO 20052992A NO 336459 B1 NO336459 B1 NO 336459B1
- Authority
- NO
- Norway
- Prior art keywords
- protein
- liver disease
- amino acid
- kda protein
- diagnosing
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 214
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 214
- 208000019423 liver disease Diseases 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title claims description 114
- 238000000338 in vitro Methods 0.000 title claims description 14
- 230000035622 drinking Effects 0.000 claims abstract description 19
- 229940106780 human fibrinogen Drugs 0.000 claims abstract description 8
- 239000003550 marker Substances 0.000 claims description 66
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 37
- 238000003745 diagnosis Methods 0.000 claims description 35
- 210000004185 liver Anatomy 0.000 claims description 22
- 238000003018 immunoassay Methods 0.000 claims description 21
- 238000002405 diagnostic procedure Methods 0.000 claims description 16
- 230000001476 alcoholic effect Effects 0.000 claims description 14
- 238000004949 mass spectrometry Methods 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 238000007792 addition Methods 0.000 claims description 7
- 238000003795 desorption Methods 0.000 claims description 7
- 239000004816 latex Substances 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 208000007848 Alcoholism Diseases 0.000 claims description 6
- 239000007857 degradation product Substances 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 229920000126 latex Polymers 0.000 claims description 5
- 238000000756 surface-enhanced laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 5
- 238000004393 prognosis Methods 0.000 claims description 4
- 238000002795 fluorescence method Methods 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 2
- 238000011002 quantification Methods 0.000 claims 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 abstract description 12
- 108010059886 Apolipoprotein A-I Proteins 0.000 abstract description 12
- 230000007423 decrease Effects 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 5
- 238000004458 analytical method Methods 0.000 abstract description 3
- 108010026552 Proteome Proteins 0.000 abstract description 2
- 238000000354 decomposition reaction Methods 0.000 abstract 3
- 102000009081 Apolipoprotein A-II Human genes 0.000 abstract 1
- 108010087614 Apolipoprotein A-II Proteins 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 30
- 101001086866 Sus scrofa Pulmonary surfactant-associated protein B Proteins 0.000 description 28
- 235000019441 ethanol Nutrition 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 101710149506 28 kDa protein Proteins 0.000 description 24
- 101710137943 Complement control protein C3 Proteins 0.000 description 24
- 101710152003 Suppressor of silencing P0 Proteins 0.000 description 24
- 238000005259 measurement Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 210000004408 hybridoma Anatomy 0.000 description 12
- 238000003491 array Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000012470 diluted sample Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- -1 poly(ethylene glycol) Polymers 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 231100000283 hepatitis Toxicity 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 4
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000011544 gradient gel Substances 0.000 description 2
- 230000002650 habitual effect Effects 0.000 description 2
- 238000003317 immunochromatography Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 2
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 101710132632 Protein C4 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000011325 biochemical measurement Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012784 weak cation exchange Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Endoscopes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002371959 | 2002-12-24 | ||
| PCT/JP2003/016600 WO2004058966A1 (ja) | 2002-12-24 | 2003-12-24 | 肝臓疾患診断用マーカー蛋白質およびそれを利用した肝臓疾患診断方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20052992D0 NO20052992D0 (no) | 2005-06-17 |
| NO20052992L NO20052992L (no) | 2005-09-14 |
| NO336459B1 true NO336459B1 (no) | 2015-08-31 |
Family
ID=32677218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052992A NO336459B1 (no) | 2002-12-24 | 2005-06-17 | Markørproteiner og in vitro metoder for diagnostisering av leversykdom og metoder for måling av protein. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7517951B2 (ja) |
| EP (1) | EP1577385B1 (ja) |
| JP (1) | JP4196948B2 (ja) |
| CN (1) | CN100384996C (ja) |
| AT (1) | ATE462001T1 (ja) |
| AU (1) | AU2003296085A1 (ja) |
| DE (1) | DE60331857D1 (ja) |
| NO (1) | NO336459B1 (ja) |
| WO (1) | WO2004058966A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4597741B2 (ja) * | 2005-03-31 | 2010-12-15 | 株式会社Ｍｃｂｉ | タンパク質、部分タンパク質および／もしくは部分ペプチド、またはそれらのプロファイルに基づく体外診断システム |
| FR2893136A1 (fr) * | 2005-11-10 | 2007-05-11 | Sanofi Aventis Sa | Procedes de diagnostic de maladies hepatiques et de criblage de molecules pour le traitement de ces maladies |
| US7750018B2 (en) * | 2006-12-06 | 2010-07-06 | Tactical Therapeutics, Inc | Use of carboxiamidotriazole (CAI) orotate in macular degeneration |
| WO2008105215A1 (ja) * | 2007-02-28 | 2008-09-04 | Nitto Boseki Co., Ltd. | アルコール性肝障害診断用マーカーペプチドおよびそれを利用したアルコール性肝障害診断方法 |
| JP2009114092A (ja) * | 2007-11-02 | 2009-05-28 | Mcbi:Kk | 慢性肝炎、肝硬変、肝がんの分別診断のための新規バイオマーカーおよび該バイオマーカーを用いた慢性肝炎、肝硬変、肝がんの分別診断方法 |
| CN102257389A (zh) * | 2008-08-28 | 2011-11-23 | 沙路特里亚制药有限责任公司 | 鉴定面临不良肝病事件风险的患者的筛选方法 |
| JP2010175452A (ja) * | 2009-01-30 | 2010-08-12 | Japan Health Science Foundation | 膵臓癌の検出法 |
| JP5585587B2 (ja) * | 2009-10-28 | 2014-09-10 | 日東紡績株式会社 | ５．９ｋＤａペプチドの免疫学的測定方法 |
| CN102507941B (zh) * | 2011-10-25 | 2014-04-30 | 北京正旦国际科技有限责任公司 | 一种肝硬化免疫质谱检测试剂盒 |
| CN102507936B (zh) * | 2011-11-09 | 2013-10-23 | 北京正旦国际科技有限责任公司 | 一种肝癌标志物多抗免疫质谱试剂盒 |
| EP3290924B1 (en) | 2011-12-01 | 2021-10-13 | Roche Diagnostics GmbH | Nt-proanp and nt-probnp for the diagnosis of stroke |
| WO2013141092A1 (ja) * | 2012-03-21 | 2013-09-26 | Tsuru Michiyo | 癌転移マーカー及びそれを用いた癌転移の診断方法 |
| CN109444405A (zh) * | 2018-10-10 | 2019-03-08 | 东南大学 | 一种基于荧光预猝灭和表面增强荧光效应的免疫检测方法 |
| CN110157792A (zh) * | 2019-04-22 | 2019-08-23 | 中山大学孙逸仙纪念医院 | 血清外泌体has_circ_0004771在制备酒精依赖综合征诊断试剂中的应用 |
| CN116041506B (zh) * | 2023-01-05 | 2023-12-05 | 深圳上泰生物工程有限公司 | 糖缺失性转铁蛋白的单克隆抗体对及检测试剂盒 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63237795A (ja) * | 1987-03-24 | 1988-10-04 | Otsuka Pharmaceut Factory Inc | アポリポタンパク質の製造法 |
| WO1994016085A2 (en) | 1992-12-30 | 1994-07-21 | Zymogenetics, Inc. | Hybrid proteins having cross-linking and tissue-binding activities |
| US5639940A (en) * | 1994-03-03 | 1997-06-17 | Pharmaceutical Proteins Ltd. | Production of fibrinogen in transgenic animals |
| ES2288962T3 (es) * | 2000-04-28 | 2008-02-01 | Bayer Aktiengesellschaft | Diagnostico de fibrosis hepatica con algoritmos de marcadores sericos. |
| CN1170943C (zh) * | 2000-10-20 | 2004-10-13 | 上海医药(集团）总公司 | 建立载脂蛋白a-i细胞靶标筛药系统及筛选升高密度脂蛋白药的方法 |
| ES2226549B1 (es) | 2002-12-18 | 2006-07-16 | One Way Liver Genomics, S.L. | Metodo para el diagnostico de esteatohepatitis no alcoholica (nash) mediante el empleo de marcadores moleculares. |
-
2003
- 2003-12-24 EP EP03786267A patent/EP1577385B1/en not_active Expired - Lifetime
- 2003-12-24 DE DE60331857T patent/DE60331857D1/de not_active Expired - Lifetime
- 2003-12-24 CN CNB2003801075522A patent/CN100384996C/zh not_active Expired - Lifetime
- 2003-12-24 JP JP2004562919A patent/JP4196948B2/ja not_active Expired - Lifetime
- 2003-12-24 AT AT03786267T patent/ATE462001T1/de not_active IP Right Cessation
- 2003-12-24 AU AU2003296085A patent/AU2003296085A1/en not_active Abandoned
- 2003-12-24 WO PCT/JP2003/016600 patent/WO2004058966A1/ja active Application Filing
- 2003-12-24 US US10/538,916 patent/US7517951B2/en active Active
-
2005
- 2005-06-17 NO NO20052992A patent/NO336459B1/no not_active IP Right Cessation
-
2009
- 2009-03-04 US US12/379,904 patent/US7781180B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN100384996C (zh) | 2008-04-30 |
| US7517951B2 (en) | 2009-04-14 |
| CN1732261A (zh) | 2006-02-08 |
| JP4196948B2 (ja) | 2008-12-17 |
| EP1577385A1 (en) | 2005-09-21 |
| NO20052992L (no) | 2005-09-14 |
| WO2004058966A1 (ja) | 2004-07-15 |
| EP1577385A4 (en) | 2006-08-23 |
| JPWO2004058966A1 (ja) | 2006-04-27 |
| NO20052992D0 (no) | 2005-06-17 |
| ATE462001T1 (de) | 2010-04-15 |
| DE60331857D1 (de) | 2010-05-06 |
| US7781180B2 (en) | 2010-08-24 |
| AU2003296085A1 (en) | 2004-07-22 |
| EP1577385B1 (en) | 2010-03-24 |
| US20060116504A1 (en) | 2006-06-01 |
| US20090275059A1 (en) | 2009-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO336459B1 (no) | Markørproteiner og in vitro metoder for diagnostisering av leversykdom og metoder for måling av protein. | |
| US8263347B2 (en) | Biomarker for diagnosis of liver disease | |
| US20190018020A1 (en) | Methods for Early Diagnosis of Kidney Disease | |
| NO338747B1 (no) | Immunanalysemetode | |
| US20080188004A1 (en) | Assay for diabetes | |
| KR101338517B1 (ko) | 인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도 | |
| CN109503713A (zh) | 抗人saa单克隆抗体及其制备方法和应用 | |
| US20060073520A1 (en) | Specific antibody directed to active hepatocyte growth factor activator and method for using the same | |
| DK2391653T3 (en) | Biomarkers associated nephropathy | |
| US20180364231A1 (en) | Method and kit for simultaneously detecting human parvovirus b19 antigen and antibody | |
| JPWO2009044561A1 (ja) | 抗ｐｒｏＮＴ／ＮＭＮモノクローナル抗体 | |
| JP5593502B2 (ja) | ケマリン濃度の測定方法 | |
| US9494600B2 (en) | Method for testing for nephritis-lesion sites and reagent therefor | |
| JP2010071788A (ja) | アルコール常習者またはアルコール常習者における肝臓疾患を判定するためのペプチドマーカーの測定法 | |
| JP2007230986A (ja) | 新規蛋白質ならびに治療、診断方法 | |
| AU2004270758A1 (en) | Assay for diabetes | |
| JP2001124778A (ja) | ガン特異タンパク質の測定方法およびガンの診断方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |